Abionyx Pharma (FRA:609) Moat Score: 0/10 (As of Jul. 04, 2026)


FRA:609 Abionyx Pharma FRA:609
19 GF Score
Price €1.99
GF Value €0.82
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Abionyx Pharma Moat Score?

Abionyx Pharma has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Abionyx Pharma has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Abionyx Pharma might have No Moat - No discernible moat.

Abionyx Pharma  (FRA:609) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Abionyx Pharma Moat Score Related Terms

FRA:609
19GF Score
Abionyx Pharma FRA:609
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Abionyx Pharma (FRA:609) Overvalued in 2026?

Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued. The current stock price of €1.99 is trading 142.7% above its estimated GF Value™ of €0.82. GuruFocus considers Abionyx Pharma to be Significantly Overvalued.

Key valuation signals for FRA:609:

  • Moat Score: 0
  • GF Value™: €0.82 vs. price of €1.99 (142.7% above fair value)
  • GF Score™: 19/100 with 4 warning signs

No single metric tells the full story. See the FRA:609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abionyx Pharma Business Description

Address 33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
19GF Score

Get the complete analysis for FRA:609

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.99
Price
€0.82
GF Value